Skip to main content
SpringerLink
Log in

Supportive Therapie und Begleitmaßnahmen beim Einsatz von Zytostatika

  • Chapter
Pharmakotherapie in der Urologie

  • 62 Accesses

Zusammenfassung

Zytostatika zählen zu den Wirkstoffen mit der geringsten therapeutischen Breite. Die zeitgerechte Applikation in adäquater Dosierung oder sogar Dosiseskalationen sind daher mit der Entstehung teilweise schwerwiegender unerwünschter Begleiterscheinungen verbunden, die je nach Substanz beispielsweise die natürliche Regenerationsfähigkeit von Zellen des Knochenmarks und der Schleimhäute oder die Funktionstüchtigkeit bestimmter Organe betreffen kann. Unter diesem Gesichtspunkt erfordert der Umgang mit den verschiedenen Zytostatika und den darauf abgestimmten Supportivtherapien nicht nur ein hohes Maß an Erfahrung, sondern auch eine enge interdisziplinäre Einbindung des Therapeuten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Adamson JW, Ludwig H (1999) Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin Alfa) in the treatment of the anemia of cancer. Oncology 56: 46–53

    Article  PubMed  CAS  Google Scholar 

  2. Alberts DS (1999) Protection by amifostine of cyclophosphamide-induced myelosuppression. Semin Oncol 26 (Suppl. 7): 37–40

    PubMed  CAS  Google Scholar 

  3. Anaissie EJ, Kiwan EN (1999) Management of febrile neutropenia in patients with hematological malignancies — an update. Hematology — American Society of Hematology Educational Program Book, pp 550–558

    Google Scholar 

  4. Anderson PM, Ramsay NKC, Shu XO et al. (1998) Effect of low-dose glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22: 339–344

    Article  PubMed  CAS  Google Scholar 

  5. Anderson PM, Schroeder G, Skubitz KM (1998) Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83: 1433–1439

    Article  PubMed  CAS  Google Scholar 

  6. Antiemetic Subcommittee of the Multinational Association of Supportive Care in cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9: 811–819

    Article  Google Scholar 

  7. ASHP Commission on Therapeutics (1999) ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56: 729–764

    Google Scholar 

  8. Baker J, McCune JS, Harvey III RD et al. (2000) Granulocyte colony-stimulating factor use in cancer patients. Ann Pharmacother 34: 851–857

    Article  PubMed  CAS  Google Scholar 

  9. Bennett CL, Smith TJ, Weeks JC et al. (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clincal Oncology Surveys regarding ASCO Clinical Practice Guidelines. J Clin Oncol 17: 3676–3681

    PubMed  CAS  Google Scholar 

  10. Bokemeyer C (2000) Dermatotoxizität antineoplastischer Substanzen. In: Schmoll, H-J, Höffken K, Possinger K (Hrsg) Kompendium internistische Onkologie; Springer, Berlin Heidelberg New York Tokyo, 3. Aufl., S 1411–1426

    Google Scholar 

  11. Bokemeyer C, Waldmann R (1998) Tumor- bzw. therapiebedingte Anämie und Erythropoietin. In: Bokemeyer C, Lipp H-P (Hrsg) Praktische Aspekte der supportiven Therapie in Hämatologie und Onkologie, Springer, Berlin Heidelberg New York Tokyo, S 12–17

    Chapter  Google Scholar 

  12. Büntzel J (1999) Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf-Hals-Tumoren. Med Klin 94 (Suppl. III): 49–54

    Article  Google Scholar 

  13. Cabriales S, Bresnahan J, Testa D et al. (1998) Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi’s sarcoma: a report of four cases. Oncol Nurs Forum 25: 67–70

    PubMed  CAS  Google Scholar 

  14. Carr DS, Noble TA (1988) Oral pilocarpine for xerostomia. Drug Intellig Clin Pharm 22: 794–795

    Google Scholar 

  15. Cascinu S (1995) Management of diarrhea induced by tumors or cancer therapy. Curr Opin Oncol 7: 325–329

    Article  PubMed  CAS  Google Scholar 

  16. Cascinu S, Fedeli A, Fedeli SL, Catalano G (1993) Octreotide versus loperamide in the treatment of fluorouracil-induec diarrhea: a randomized trial. J Clin Oncol 11: 148–151

    PubMed  CAS  Google Scholar 

  17. Ciernik IF, Schnaz U, Gmür J (1999) Delaying treatment with granulocyte colony-stimulating factor after allogenic bone marrow transplantation for hematological malignancies: a prosepctive randomized trial. Bone Marrow Transplant 24: 147–151

    Article  PubMed  CAS  Google Scholar 

  18. Cockerham MB, Weinberger BB, Lerchie SB (2000) Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplanatation. Ann Pharmacother 34: 300–303

    Article  PubMed  CAS  Google Scholar 

  19. Comas D, Mateu J (1996) Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion. Ann Pharmacother 30: 244–246

    PubMed  CAS  Google Scholar 

  20. Crouch MA, Restino MS, Cruz JM et al. (1996) Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmcother 30: 331–336

    CAS  Google Scholar 

  21. Decker-Baumann C, Buhl K, Frohmüller S et al. (1999) Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 35: 202–207

    Article  PubMed  CAS  Google Scholar 

  22. De Lalla F (1997) Antibiotic treatment of febrile episodes in neutropenic cancer patients — Clinical and economic considerations. Drugs 53(5): 789–804

    Article  PubMed  Google Scholar 

  23. DeSpain JD (1992) Dermatological toxicity of chemotherapy. Semin Oncol 19: 501–507

    PubMed  CAS  Google Scholar 

  24. Dicato M, Duhem C, Bercehm G, Ries F (2000) Clinical benefit from erythropoietin. Curr Opin Oncol 12: 297–302

    Article  PubMed  CAS  Google Scholar 

  25. Dickson TMC, Wong RM, Negrin RS et al. (2000) Effect of oral glutamine supplementation during bone marrow transplantation. JPEN 24: 61–66

    Article  CAS  Google Scholar 

  26. Dodd MJ, Dibble SL, Miaskowski C et al. (2000) Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90: 39–47

    Article  PubMed  CAS  Google Scholar 

  27. Dorr RT (1999) Managing extravasations of vesicant chemotherapy drugs. In: Lipp H-P (ed): Anticancer drug toxicity; prevention, management and clinical pharmacokinetics, Dekker, New York Basel, pp 279–318

    Google Scholar 

  28. Dorr RT, Holmes BC (1999) Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol 26 (Suppl. 7): 108–119

    PubMed  CAS  Google Scholar 

  29. Dorr VJ (1998) A practitioner’s guide to cancer-related alopecia. Semin Oncol 25: 562–570

    PubMed  CAS  Google Scholar 

  30. Duvic M, Lemak NA, Valero V et al. (1996) A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad.Dermatol 35: 74–78

    Article  PubMed  CAS  Google Scholar 

  31. Epstein JB, Wong FLW (1994) The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 28: 693–698

    Article  PubMed  CAS  Google Scholar 

  32. Essayan DM, Kagey-Sobotka A, Colarusso PJ et al. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97: 42–46

    Google Scholar 

  33. Etminan M, Wright JM, Carleton BC Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice. Ann Pharmacother 32: 1193–1200

    Google Scholar 

  34. Fidler P, Loprinzi CL, O’Fallon JR et al. Prospective evaluation of a chamomile mouthwash for prvention of 5-FU-induced oral mucositis. Cancer 77: 522–525

    Google Scholar 

  35. Fleming RA, Cruz JM, Webb CD et al. (1996) Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna. Bone Marrow Transplant 17: 497–501

    PubMed  CAS  Google Scholar 

  36. Foote RL, Loprinzi CL., Frank AR et al. (1994) Randomized trial of a chlorhexidine mouthwash for alleviation of a radiation-induced mucositis. J Clin Oncol 12: 2630–2633

    PubMed  CAS  Google Scholar 

  37. Foster-Nora JA, Siden R (1997) Amifostine for protection from antineoplastic drug therapy. Am J Health Syst Pharm 54: 787–800

    PubMed  CAS  Google Scholar 

  38. Frakes LA, Brehm TL, Kosty MP et al. (1997) An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 20: 473–478

    Article  PubMed  CAS  Google Scholar 

  39. Franzen L, Henriksson R, Littbrand B, Zackrisson B (1995) Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. Acta Oncol 34: 219–223

    Article  PubMed  CAS  Google Scholar 

  40. Garewal HS, Dalton WS (1985) Metoclopramide in vincristine induced ileus. Cancer Treat Rep 69: 1309–1311

    PubMed  CAS  Google Scholar 

  41. Glisson SD, LaRocca RV, Rice MK et al. (2000) Irinotecan (CPT-11) with atropine for colorectal patients delivered on an every-other-week schedule does not cause acute diarrhea. Proc ASCO 19: A2452

    Google Scholar 

  42. Goedhals L, Heron J.-F, Kleisbauer J-P et al. (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study. Ann Oncol 9: 661–666

    Article  PubMed  CAS  Google Scholar 

  43. Gralla RJ A new class of antiemetics (NK-1 Receptor Antagonists) demonstrate promise in initial comparison studies. Opin Topics Support Care Oncol 31: 1–3

    Google Scholar 

  44. Gralla RJ, Osoba D, Kris MG et al. (1999) Recommendations for the use of antiemetics: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 17: 2971–2994

    PubMed  CAS  Google Scholar 

  45. Gregory RE, Ettinger DS (1998) 5-HT3-Receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting — A comparison of their pharmacology and clinical afficacy. Drugs 55: 173–189

    Article  PubMed  CAS  Google Scholar 

  46. Greil R (1998) Einsatz hämatopoetischer Wachstumsfaktoren in der Therapie hämatologischer und onkologischer. Krankheiten Onkologie 21: 527–532

    Article  Google Scholar 

  47. Grené N, Pointereau-Bellanger A, Conort O et al. (2000) Multicenter study of the impact of prescription guidelines on the use of colony stimulating factors. Anticancer Drugs 11: 109–115

    Article  PubMed  Google Scholar 

  48. Hartmann JT, Knop S, Fels LM et al. (2000) The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. Anticancer Drugs 11: 1–6

    Article  PubMed  CAS  Google Scholar 

  49. Hartmann T, Fels LM, Knop S et al. (2000) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs 18: 281–289

    Article  PubMed  CAS  Google Scholar 

  50. Hensley ML, Schuchter LM, Lindley C et al. (1999) American Society of Clinical Oncology: Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17: 3333–3355

    PubMed  CAS  Google Scholar 

  51. Herman EH, Zhang J, Lipshultz SE et al. (1999) Correlation between serum levels of cardiac Troponin-T and the Severity of the chronic cardiomyopathy induced by Doxorubicin. J Clin Oncol 17: 2237–2243

    PubMed  CAS  Google Scholar 

  52. Hesketh PJ, Gralla RJ, Webb RT et al. (1999) Randomized Phase-II-Study of the neurokinin1-receptor-antagonist CJ 11974 in the control of cisplatin-induced emesis. J Clin Oncol 17: 338–343

    PubMed  CAS  Google Scholar 

  53. Hesketh PJ, Kris MG, Grunberg SM et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103–109

    PubMed  CAS  Google Scholar 

  54. Hesketh PJ, Crews JR, Cohen R et al. (1999) Efficacy of a single 1-mg or 2-mg dose of oral granisetron for the prevention of nausea and vomiting induced by intravenous cyclophos-phamide- or carboplatin-based chemotherapy regimens. Proc ASCO 18: A2290

    Google Scholar 

  55. Hilkens PHE, Verweij J, Vecht CJ et al. (1997) Clinical charcateristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 10: 187–190

    Article  Google Scholar 

  56. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC (1998) Mechanism and management of antibiotic-associated diarrhea. Clin Infect Dis 27: 702–710

    Article  PubMed  Google Scholar 

  57. Hoekman K, van der Vijgh WJF, Vermorken JB (1999) Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 57: 133–155

    Article  PubMed  CAS  Google Scholar 

  58. Hoelzer D (1997) Hematopoietic growth factors — not whether, but when and where. N Engl J Med 336: 1822–1824

    Article  PubMed  CAS  Google Scholar 

  59. Holzhauer P (2000) Positiver Einfluss von Selen auf die Häufigkeit und den Schweregrad der durch Vinorelbin induzierten lokalen Phlebitis bei Tumorpatienten. Biosynthesen 2: 14–15

    Google Scholar 

  60. Hughes WT, Armstrong D, Bodey GP et al. (1997) Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. Clin Infect Dis 25: 551–573

    Article  PubMed  CAS  Google Scholar 

  61. Italian Group for Antiemetic Research (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16: 2937–2942

    Google Scholar 

  62. Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342: 1554–1559

    Article  Google Scholar 

  63. Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9: 759–765

    Article  Google Scholar 

  64. Jebb SA, Osborne RJ, Maughn TS (1994) 5-Fluorouracil and folinic acid-induced mucositis: no effect of glutamine supplementation. Br J Cancer 70: 732–735

    Google Scholar 

  65. Johnston EM, Crawford J (1998) Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol 25: 552–561

    PubMed  CAS  Google Scholar 

  66. Karthaus M, Rosenthal C, Huebner G et al. (1998) Effect of topical oral G-CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant 22: 781–785

    Article  PubMed  CAS  Google Scholar 

  67. Karthaus M, Rosenthal C, Ganser A (1999) Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis — Are there new strategies? Bone Marrow Transplant 24: 1095–1108

    Article  PubMed  CAS  Google Scholar 

  68. Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36: 766–771

    Article  PubMed  CAS  Google Scholar 

  69. Katz A, Epelman S, Anelli A et al. (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121: 128–131

    Article  PubMed  CAS  Google Scholar 

  70. Kaushansky K (1998) Thrombopoietin. N Engl J Med 339: 746–754

    Article  PubMed  CAS  Google Scholar 

  71. Kern WV, Cometta A, De Bock R et al. (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341: 312–318

    Article  PubMed  CAS  Google Scholar 

  72. Kibbler CC, Prentice HG (1999) Pathogen “shift” in febrile neutropenia. Curr Opin Infect Dis 12: 351–354

    Article  PubMed  CAS  Google Scholar 

  73. Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41 (Suppl. D): 13–24

    Article  PubMed  CAS  Google Scholar 

  74. Klastersky J (1999) Infection in the neutropenic patient and stem cell transplant patient. Curr Opin Infect Dis 12: 355–358

    Article  PubMed  CAS  Google Scholar 

  75. Klein HG (1994) Immunologic aspects of blood transfusion. Semin Oncol 21 (Suppl. 3): 16–20

    PubMed  CAS  Google Scholar 

  76. Kraft A, Weinig S, Edinger M, Winterthaler BR (2000) Anthrazyklin-Extravasate: Behandlungsrichtlinien und Literaturübersicht. Onkologe 6: 674–686

    Article  Google Scholar 

  77. Kurbacher CM, Mallmann PK (1998) Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res 18: 2203–2210

    PubMed  CAS  Google Scholar 

  78. Labar B, Mrsic M, Pavletic Z et al. (1993) Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11: 379–382

    PubMed  CAS  Google Scholar 

  79. Langer SW, Sehested M, Jensen PB et al. (2000) Dexrazoxane in anthracycline extravasation. J Clin Oncol 18: 3064

    PubMed  CAS  Google Scholar 

  80. Lenfers BHM, Löffler TM, Dröge C et al. (1999) Activity of orally administered budesonide in patients with Irinotecan (CPT-11) induced diarrhea. Proc ASCO 18: A2259

    Google Scholar 

  81. Lindley C, Blower P (2000) Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 57: 1685–1697

    PubMed  CAS  Google Scholar 

  82. Links M, Lewis C (1999) Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 57: 293–308

    Article  PubMed  CAS  Google Scholar 

  83. Lipp H-P (1999) Kardiotoxizität von Anthracyclinen und strukturverwandten Verbindungen — Pharmakokinetische Aspekte, Strategien zur Toxizitätsreduktion und Überlegungen zur Dosiseskalation Krankenhauspharmazie 20: 371–379

    Google Scholar 

  84. Lipp H-P, Bokemyer C (2000) Supportivtherapie in der klinischen Onkologie — Aktueller Stand und Perspektiven. Krankenhauspharmazie 21: 559–575

    Google Scholar 

  85. Lipp H-P, Hebart H, Faul C, Einsele H (1998) Antimikrobielle Prophylaxe und Therapie bei neutropenischen Patienten. In: Bokemyer C, Lipp H-P. (Hrsg) Praktische Aspekte der supportiven Therapie in Hämatologie und Onkologie; Springer, Berlin Heidelberg New York Tokyo, S 23–43

    Chapter  Google Scholar 

  86. Lipp H-P (1999) Dermatological toxicity and hypersensitivity reactions associated with the use of cytostatics. In: Lipp H-P (ed) Anticancer drug toxicity; prevention, management and clinical pharmacokinetics, Dekker, New York Basel, pp 263–275

    Google Scholar 

  87. Lopez M, Vici P, Di Lauro L et al. (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16: 86–92

    PubMed  CAS  Google Scholar 

  88. Loprinzi CL, Alberts SR, Christensen BJ et al. (2000) History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clin Proc 75: 303–309

    PubMed  CAS  Google Scholar 

  89. Marks JE (1997) Mucosal protectants and their application for head and neck chemoirradiation. Curr Opin Oncol 9: 267–273

    Article  PubMed  CAS  Google Scholar 

  90. Martenson JA, Bollinger JW, Sloan JA et al. (2000) Sucralfate in the prevention of treatmentinduced diarrhea in patients receiving pelvic radiation therapy: a North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial. J Clin Oncol 18: 1239–1245

    PubMed  CAS  Google Scholar 

  91. Melko GP, Turco TF, Phelan TF, Sauers NM (1999) Treatment of radiation-induced proctitis with sucralfate enemas. Ann Pharmacother 33: 1274–1276

    Article  PubMed  CAS  Google Scholar 

  92. Mercadante S, Gebbia V, Marrazzo A, Filosto S (2000) Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26: 303–311

    Article  PubMed  CAS  Google Scholar 

  93. Miyazaki M, Fujiwara Y, Isobe T et al. (1999) The relationship between Carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Res 19: 667–670

    PubMed  CAS  Google Scholar 

  94. Muscaritoli M, Micozzi A, Conversano L et al. (1997) Oral glutamine in the prevention of chemotherapy-induced gastrointestinal toxicity. Eur J Cancer 33: 319–320

    Article  PubMed  CAS  Google Scholar 

  95. Navari RM, Feinhardt RR, Gralla RJ et al. (1999) Reduction of cispatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340: 190–195

    Article  PubMed  CAS  Google Scholar 

  96. Nohynek GJ, Plard JP, Wells MY, Zerial A, Roquet F (1997) Comparison of the potency of glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Cancer Chemother Pharmacol 39: 259–266

    Article  PubMed  CAS  Google Scholar 

  97. Oblon DJ, Paul SR, Oblon MB, Malik S (1997) Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant 20: 961–963

    Article  PubMed  CAS  Google Scholar 

  98. Okuno SH, Foote RL, Loprinzi CL et al. (1997) A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 79: 2193–2199

    Article  PubMed  CAS  Google Scholar 

  99. Oppenheim BA (1998) The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 41 (Suppl. D): 7–11

    Article  PubMed  CAS  Google Scholar 

  100. Ozer H, Armitage JO, Bennett CL et al. (2000) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558–3585

    PubMed  CAS  Google Scholar 

  101. Peterson DE (1999) Recent advances in oral mucositis. Curr Opin Oncol 11: 261–266

    Article  PubMed  CAS  Google Scholar 

  102. Phillips K-A, Tannock IF (1998) Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 16: 3179–3190

    PubMed  CAS  Google Scholar 

  103. Pitten F-A, Kramer A (1999) Antimcrobial efficacy of antiseptic mouthrinse solutions. Eur J Clin Pharmacol 55: 95–100

    Article  PubMed  CAS  Google Scholar 

  104. Protenoy RK (1987) Constipation in the cancer patient: causes and management. Med Clin North Am 71: 303–311

    Google Scholar 

  105. Price VH (1999) Treatment of hair loss. N Engl J Med 341: 964–973

    Article  PubMed  CAS  Google Scholar 

  106. Quock J, Dea G, Lim N et al. (1999) Premedication strategy for weekly paclitaxel based on experiences with 1608 infusions of 3- and 4-week paclitaxel. Proc Am Soc Clin Oncol 18: A635

    Google Scholar 

  107. Roffe C (1996) Biotherapy for antibiotic-associated and other diarrhea. J Infect 32: 1–10

    Article  PubMed  CAS  Google Scholar 

  108. Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E, Gutierrez M (2000) Racecadodril in the treatment of acute watery diarrhea in children. N Engl J Med 343: 463–467

    Article  PubMed  CAS  Google Scholar 

  109. Salzberg M, Herrmann R (2000) Das Hand-Fuss-Syndrom (palmar-plantare Erythrodysästhesie). Schweiz Med Wochenschr 130: 1413–1416

    PubMed  CAS  Google Scholar 

  110. Seber A, Shu XO, Defor T, Sencer S, Ramsay N. (1999) Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 23: 35–40

    Article  PubMed  CAS  Google Scholar 

  111. Shapiro J, Richardson GE (1994) Paclitaxel-induced “recall” soft tissue injury occuring at the site of the previous extraysation with subsequent intravenous treatment in a different limb. J Clin Oncol 12: 2237–2238

    PubMed  CAS  Google Scholar 

  112. Shaw L, Bonner H, Schuchter L et al. (1999) Pharmacokinetics of amifostine in cancer patients: the data support nonlinear kinetics. Proc A. Soc. Clin Oncol 18: A727

    Google Scholar 

  113. Simon AM, Zittoun R (1999) Fatigue in cancer patients. Curr Opin Oncol 11: 244–249

    Article  PubMed  CAS  Google Scholar 

  114. Slee PHTJ (1997) Nail changes after chemotherapy. N Engl J Med 338: 168

    Article  Google Scholar 

  115. Sredni B, Albeck M, Tichler T et al. (1995) Bone marrow-sparing and prevention of alopecia by AS 101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 13: 2342–2353

    PubMed  CAS  Google Scholar 

  116. Steward WP (1993) Granulocyte and granulocyte-macrophage colony-stimulating factor. Lancet 342: 153–156

    Article  PubMed  CAS  Google Scholar 

  117. Tepler I, Elias L, Smith JW et al. (1996) A randomized placbo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87: 3607–3614

    PubMed  CAS  Google Scholar 

  118. Teramura M, Kobayashi S, Yoshinaga K et al. (1996) Effect of oprelvekin on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol 38 (Suppl.): S99-S102

    Article  PubMed  CAS  Google Scholar 

  119. Toner GC, Shapiro JD, Laidlaw CR et al. (1998) Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized crossover comparison. J Clin Oncol 16: 3874–3879

    PubMed  CAS  Google Scholar 

  120. Torres Gomez A, Jimenez MA, Alvarez MA et al. (1995) Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation — A retrospective randomized study. Ann Hematol 71: 65–70

    Article  Google Scholar 

  121. Valdez IH, Wolff A, Atkinson JC et al. (1993) Use of pilocarpine during head and neck radiation to reduce xerostomia and salivary dysfunction. Cancer 71: 1848–1851

    Article  PubMed  CAS  Google Scholar 

  122. Vadhan-Raj S, Verschraegen CF, Buesno-Ramos C et al. (2000) Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132: 364–368

    Article  PubMed  CAS  Google Scholar 

  123. Van der Klauw MM, Gousmit R, Halie R et al. (1999) A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159: 369–374

    Article  PubMed  Google Scholar 

  124. Verdi CJ (1993) Cancer therapy and oral mucositis. Drug Safety 9(3): 185–195

    Article  PubMed  CAS  Google Scholar 

  125. Vivino FB, Al-Hashimi I, Khan Z et al. (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome. Arch Intern Med 159: 174–181

    Article  PubMed  CAS  Google Scholar 

  126. Wadler S, Benson III AB, Engelking C et al. (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16: 3169–3178

    PubMed  CAS  Google Scholar 

  127. Wasserman E, Hidalgo M, Hornedo J, Cortes-Funes H (1997) Octreotide (SMS 201–995) for hematopoietic support-dependent high-dose chemotherapy-related diarrhea: dose finding study and evaluation of efficacy. Bone Marrow Transplant 20: 711–714

    Article  PubMed  CAS  Google Scholar 

  128. Webb IJ, Anderson KC (1999) Risks, costs and alternatives to platelet transfusions. Leuk Lymph 34: 71–84

    CAS  Google Scholar 

  129. Weiß J, Wellens W (1999) The addition of human albumin to vinorelbine solution prevents venous irritation. Onkologie 22: 416–418

    Article  Google Scholar 

  130. Weiß B, Einsele H, Wütz A, Kanz L, Bokemyer C (2000) Supportivtherapie im Rahmen der Hochdosis-Chemotherapie — Zusammenarbeit mit dem Pflegeteam. Onkologe 6: 501–508

    Article  Google Scholar 

  131. Wenisch C, Parschalk B, Hasenhündl M et al. (1996) Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of clostridium difficlie-associated diarrhea. Clin Infect Dis 22: 813–818

    Article  PubMed  CAS  Google Scholar 

  132. Wilkes JD (1998) Prevention and Treatment of Oral Mucositis following Cancer Chemotherapy. Semin Oncol 25: 538–551

    PubMed  CAS  Google Scholar 

  133. Wiseman LR, Spencer CM (1998) Dexrazoxane — A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 56(3): 385–403

    Article  PubMed  CAS  Google Scholar 

  134. Wymenga ANM, van der Graaf WTA, Hofstra LS et al. (1999) Phase I study of transforming growth factor ß3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res 5; 1363–1368

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H.-P. Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Michael C. Truss , Christian G. Stief , Stefan Machtens  & Udo Jonas (Direktor), ,  &  (Direktor)

  2. Zentrum Anästhesiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Till Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lipp, HP., Bokemeyer, C. (2002). Supportive Therapie und Begleitmaßnahmen beim Einsatz von Zytostatika. In: Truss, M.C., Stief, C.G., Machtens, S., Jonas, U., Wagner, T. (eds) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09273-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09273-6_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41519-0

  • Online ISBN: 978-3-662-09273-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation